Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg, Department of Otolaryngology, Head & Neck Surgery, Friedrich-Alexander University Erlangen-Nürnberg (FAU), University Hospital Erlangen, Waldstraße 1, 91054, Erlangen, Germany.
Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg, Department of Pathology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), University Hospital Erlangen, Krankenhausstraße 8-10, 91054, Erlangen, Germany.
Eur Arch Otorhinolaryngol. 2023 Dec;280(12):5489-5497. doi: 10.1007/s00405-023-08115-5. Epub 2023 Jul 28.
The following study aimed to answer the question if HPV-HNCUP and HPV-OPSCC are the same disease. Propensity score matching (PSM) was used to compare the oncological outcomes of both groups, in particular the 5-year overall survival rate (OS), the 5-year disease specific survival rate (DSS) and the 5-year progression free survival rate (PFS).
Firstly, between January 1st, 2007, and March 31st, 2020 a total of 131 patients were treated with HNCUP at our Department. Out of these, 21 patients with a confirmed positive p16 status were referred to surgery followed by adjuvant therapy. Secondly, between January 1st, 2000, and January 31st, 2017, a total of 1596 patients were treated with an OPSSC at our Department. Out of these, 126 patients with a confirmed positive p16 status were referred to surgery followed by adjuvant therapy. After PSM, 84 patients with HPV-OPSCC and 21 HPV-HNCUP remained in the study for further comparison.
The OS was 63.5% (95% CI 39.4-87.6) for HPV-HNCUP and 88.9% (95% CI 90.4-100.0) for HPV-OPSCC patients and therefore, significantly lower for the first mentioned (p = 0.013). The DSS was also significantly impaired for HPV-HNCUP (71.0%, 95% CI 46.3-95.7), in comparison with HPV-OPSCC patients (95.5%, 95% CI 90.4-100.0; p = 0.002). The PFS for HPV-HNCUP patients was lower (75.6%, 95% CI 54.0-97.2) yet not significantly different to HPV-OPSCC (90.4%, 95% CI 83.5-97.3; p = 0.067).
The results presented demonstrate a significant reduced OS and DSS for HPV-HNCUP patients. Accordingly, in our study HPV-HNCUP and HPV-OPSCC are two different entities with a different oncological outcome.
本研究旨在回答 HPV-HNCCUP 和 HPV-OPSCC 是否为同一种疾病。我们使用倾向评分匹配（PSM）来比较两组的肿瘤学结局，特别是 5 年总生存率（OS）、5 年疾病特异性生存率（DSS）和 5 年无进展生存率（PFS）。
首先，2007 年 1 月 1 日至 2020 年 3 月 31 日期间，我们科室共收治了 131 例 HNCCUP 患者，其中 21 例 p16 阳性患者接受了手术及辅助治疗。其次，2000 年 1 月 1 日至 2017 年 1 月 31 日期间，我们科室共收治了 1596 例 OPSSC 患者，其中 126 例 p16 阳性患者接受了手术及辅助治疗。经过 PSM 后，84 例 HPV-OPSCC 患者和 21 例 HPV-HNCCUP 患者纳入研究进一步比较。
HPV-HNCCUP 患者的 OS 为 63.5%（95%CI 39.4-87.6），HPV-OPSCC 患者为 88.9%（95%CI 90.4-100.0），前者显著低于后者（p=0.013）。HPV-HNCCUP 患者的 DSS 也显著受损（71.0%，95%CI 46.3-95.7），与 HPV-OPSCC 患者相比（95.5%，95%CI 90.4-100.0；p=0.002）。HPV-HNCCUP 患者的 PFS 较低（75.6%，95%CI 54.0-97.2），但与 HPV-OPSCC 患者相比无显著差异（90.4%，95%CI 83.5-97.3；p=0.067）。
本研究结果表明，HPV-HNCCUP 患者的 OS 和 DSS 显著降低。因此，在我们的研究中，HPV-HNCCUP 和 HPV-OPSCC 是两种不同的实体，具有不同的肿瘤学结局。
